Entrevista Dr. Emilio Pizzichini
1. WENZEL, SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med, 18(5): 716-25, 2012.
2. KATZ, LE. et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc, 11(4): 531-6, 2014.
3. NEJMAN-GRYZ, P. et al. Epithelial derived cytokines IL-25, IL-33 and TSLP in obstructive lung diseases. In: ERS, 2017, Milão. PA571. Disponível em: < http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.
BR/RESP/0129/17b – Setembro/2017
Entrevista Dr. Carlos Jardim
1. RAINA, A.; HUMBERT, M. Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 25: 390-398, 2016.
2. SIMONNEAU, G. et al. Future perspectives in pulmonary arterial hypertension. European Respiratory Review, 25: 381-389, 2016.
3. GRAARUP, J. et al. Patient engagement and self-management in pulmonary arterial hypertension. European Respiratory Review, 25: 399-407, 2016
4. ARMSTRONG, I. et al. PHA-UK living with Pulmonary Hypertension 2016 Survey. In: ERS, 2017, Milão. PA2419. Disponível em: <http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.
BR/RESP/0129/17c – Setembro/2017
Entrevista Dr. José Jardim
5. VESTBO, J. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). European Respiratory Journal, 31: 869-87, 2008.
6. MILLER, BE. et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med, 193(6): 607-13, 2016.
7. LOMAS, DA. et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax, 63 1032-1034, 2008.
8. CHRISTENSON, SA. et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 191(7): 758–66, 2015.
9. OBEIDAT, M. et al. Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respir Med, 3: 782–95, 2015.
10. GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. Global strategy for the Diagnosis, Management and Prevention of COPD. Updated 2017. Disponível em: <http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/>. Acesso em: 14 set. 2017.
11. DONALDSON, GC. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57: 847-852, 2002.
12. DONALDSON, GC. et al. Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD. Chest, 128: 1995–2004, 2005.
BR/RESP/0129/17e – Setembro/2017
Entrevista Dr. Ronald Dahl
1. POBEREZHETS, V. et al. Clinical features and quality of life in patients with different metabolic phenotypes of COPD. In: ERS, 2017, Milão. PA3673. Disponível em: <http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.
2. HOHFELD, JM. et al. Late Breaking Abstract – Lung deflation with Indacaterol-Glycopyrronium improves cardiac function in COPD patients: The CLAIM Study. In: ERS, 2017, Milão. OA2899. Disponível em: <http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.
3. RUBIO, CM. et al. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. Int J Chron Obstruct Pulmon Dis, 12: 2373-83, 2017.
4. LOUREIRO, CC. et al. Blurred lines. Eosinophilic COPD: ACOS or COPD phenotype? Rev Port Pneumol, 22(5): 279-82, 2016.
BR/RESP/0129/17f – Setembro/2017
Entrevista Dr. Paulo Zimermann
1. BOHN JR., I. et al. Pulmonary Rehabilitation in COPD Phenotype Exacerbator. In: ERS, 2017, Milão/Itália. Thematic Poster: Pulmonar Rehabilitation in Patients with Chronic Lung Diseases. PA758. Disponível em: <http://ers-eposter.key4events.com/42/52480.pdf>. Acesso em: 14 set. 2017.